VERTIS CV Trial: The SGLT-2 inhibitors are the next generation drugs for type 2 diabetes as well as patients with heart failure. We have seen…
The SGLT-2 inhibitors were initially developed for diabetes but eventually noted to have significant effects on outcomes in patients with heart failure in addition to…
The VICTORIA trial was a randomized controlled trial that tested the use of vericiguat in patients with heart failure with reduced ejection fraction. Vericiguat is…
COAPT Trial Summary Objective The goal of the COAPT trial was to evaluate the safety and effectiveness of transcatheter mitral-valve repair in patients with heart…